Objective
The Ebola virus disease (EVD) epidemic in West Africa is not under control. This proposal has immediate, mid-term and long-term objectives to combat the current and future EVD epidemics. Objectives with immediate impact are: (i) Providing key information needed to implement efficient convalescent plasma treatment and a toolkit to determine the suitability of plasma for treatment; (ii) Providing key information needed to estimate the efficacy of experimental vaccines, including correlates of protection at T cell level; (iii) Improving supportive treatment of patients and reducing hospital case fatality rate by providing information on biomarkers and relevant co-infections; (iv) Monitoring development of mutations in Ebola virus (EBOV) genomes during the epidemic and enhancing our preparedness to determine the relevance of these changes in experimental systems; and (v) Protecting health care workers and communities by providing information on virus shedding in body fluids and estimation of infectiousness in various stages of EVD. Objectives with mid to long-term impact are: (i) Provide information on pathophysiological changes and immunological determinants to infer new immunotherapeutic strategies for treatment of EVD; and (ii) Strengthening cooperation of biosafety level 4 (BSL-4) facilities and building a pan-European research area in the field of highly pathogenic viruses as envisaged in the ‘European Research Infrastructure on Highly Pathogenic Agents’ project. The concept of EVIDENT is to scientifically exploit specimens collected from EVD patients during outbreak response and field research. We will use state-of-the-art methodologies within the EU BSL-4 facilities to gather new and outbreak-relevant knowledge on B and T cell immunology, biomarkers, virus evolution, virulence determinants, and transmission of EBOV. The consortium contributes to the outbreak response since March 2014 and is competent to implement a project in the outbreak area.
Fields of science
- natural sciencesbiological sciencesmicrobiologyvirology
- natural sciencesbiological sciencesgeneticsmutationvirus mutation
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesebola
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
20359 Hamburg
Germany
See on map
Participants (11)
1018 DD Amsterdam
See on map
LS2 7UE Leeds
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
L69 7ZX Liverpool
See on map
00149 Roma
See on map
53123 Bonn
See on map
35037 Marburg
See on map
13353 Berlin
See on map
1097 Budapest
See on map
1000 Ljubljana
See on map
75654 Paris
See on map
66386 St Ingbert
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.